Modeling Human Diseases in the Nematode Caenorhabditis elegans

Marvin L. Bayne, Ph.D.
Fellow
Charles A Dana Research Institute for Scientist Emeriti
Drew University
Education and Training

• AB Biology
  Western Maryland College
  (now McDaniel College)

• MS and PhD Biochemistry and Molecular Biology
  Northwestern University

• Post-Doctoral Training
  Johns Hopkins University
Work Experience

- Unigene Laboratories 2.5 years
- Merck Research Laboratories 11 years
- Schering-Plough Research Institute 14 years
- Merck Research Laboratories 1 year

- Charles A Dana Research Institute for Scientists Emeriti 2016-
Research Topics

• Mechanism and Enzymology of DNA Replication
• Gene Synthesis, Recombinant Protein Expression, and Protein Engineering
• G Protein-Coupled Receptor Cloning and Drug Development Programs
• Genomics, Biomarkers, Translational Research
• **Molecular Neurobiology of Caenorhabditis elegans**
“Thus we want a multicellular organism which has a short life cycle, can be easily cultivated, and is small enough to be handled in large numbers, like a micro-organism. It should have relatively few cells, so that exhaustive studies of lineage and patterns can be made, and should be amenable to genetic analysis.” --Excerpts from Proposal to the Medical Research Council, 1963
C. elegans as a Model System

• Easy to Cultivate
  – Small: ~1mm in length
  – Grown on agar plates of E. coli bacteria, can be scaled up in liquid culture
  – Large brood size: ~300; short generation time: ~3 days

• Genetic Analysis Tools
  – Forward Genetics:
    • EMS mutagenesis, transposons mutagenesis
    • Self fertilizing hermaphrodites allows easy clonal expansion
  – Reverse Genetics:
    • Gene Knockouts/Replacements: CRISPR/Cas-9
    • Gene Knockdowns thru RNAi bacterial delivery system

• Transparent:
  – Allows use of Green Fluorescent Protein tagged promoter fusions and proteins to follow expression in vivo

• Can be used to Model Human Diseases
  – ~ 60-80% of C. elegans genes have human counterparts
  – ~42% of human disease genes have C. elegans counterparts
  – Can generate “humanized” worms; replace worm gene with human counterpart
C. Elegans Milestones

- 1963: Brenner proposal
- 1998: First multicellular organism fully sequenced
- 2002: Cell Lineage Nobel Prize to Brenner, Horvitz and Saulston
- 2006: RNAi discovery Nobel Prize to Fire and Mello
- 2008: Nobel Prize to Chalfie for GFP in C. elegans
- 2011: First connectome completed
Resources Available

- *C. elegans* Genetic Stock Center, U of Minnesota
  - Mutant stocks, knockouts and point mutations
  - GFP fusions
  - Wild type strains from different ecosystems
  - Related, sequenced species eg *C. briggsea*

- *C. elegans* scientific community
  - WormBook
  - WormBase
  - Worm Breeder’s Gazette
  - New York Area Worm Discussion Group
Role of *C. elegans* Research in Drug Discovery

- Target identification
- Mechanism of action studies
  - Traditional Chinese Medicines
- Identification of off-target effects
  - Clozapine
- Phenotypic screening
- “Humanized” worms for lead identification
C. elegans Models of Human Disease

- **Neurobiology**
  - Alzheimer’s Disease
  - Parkinson’s Disease
  - Huntington’s Disease
  - Nicotine addiction
  - ALS
  - Autism Spectrum Disorders

- **Metabolic Disease**
  - Insulin signalling and resistance
  - Fat accumulation

- **Aging**

- **Cancer pathways**
Nervous System of C. elegans

• 302 neurons out of a total of 959 cells
  – 32 chemosensory neurons
  – 8 dopamine neurons

• Complete “connectome” determined
  – 6393 chemical synapses
  – 1410 neuromuscular junctions
  – 890 gap junctions
Bayne Lab 2019
Stefanie DeFronzo, Lexi Holroyd, Erin Heller, Shivani Mody, Karishma Patel, Stephanie Wang, Mehek Agrawal, Krishna Patel

• Current Projects
  – Parkinson’s Disease
  – Autism Spectrum Disorder
Parkinson’s Disease

Parkinson’s disease is a degenerative neurological disease affecting dopamine producing neurons.

Damage to dopaminergic neurons can be caused by genetic defects, environmental factors such as exposure to neurotoxins like pesticides, or traumatic brain injury.

Symptoms include tremors, slowness of movements, gait problems.
C. elegans Models of Parkinson's Disease

- **Genetic**: *C. elegans* strains expressing human PD related genes resulting in age-dependent degeneration of dopaminergic neurons
  - Alpha-synuclein: A53T mutation
  - LRRK2: G2019S mutation
- **Neurotoxins**: chemical degeneration of dopamine neurons
  - MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
  - 6-OHDA (6-hydroxyl dopamine)
- Degeneration of dopamine neurons can be monitored using *Green Fluorescent Protein* specifically in the 8 dopaminergic neurons
- Parkinson’s model worms develop movement abnormalities mimicking movement disorders in Parkinson’s disease patients
  - Swim to crawl paralysis, swimming induced paralysis
- We are using these models to identify drugs and/or genes that protect dopamine neurons
Dopamine Neurons Expressing GFP
C. elegans MGM7
Melissa Medina C’17
6-OHDA Damage to C. elegans Dopamine Neurons inhibited by Dopamine Transporter Antagonists

Worm Models of Parkinson’s Disease

• VM6365  pdat-1::GFP, pdat-1::ICE
  – Reported loss of GFP (DA neurons) in late L1 stage
  – No GFP staining in adults

• JVR203  pdat-1::GFP, pdat-1::α-synuclein (A53T)
  – Age dependent loss of dopamine neurons

• JVR168  pdat-1::GFP, pdat-1::LRRK2 (G2019S)
  – Age dependent loss of dopamine neurons

• Dat-1
  – loss of activity mutation in dopamine transporter

• Cat-2
  – mutation in biosynthesis of dopamine

• Dop-3
  – mutation in dopamine receptor
Worm Models of Parkinson’s Disease

- **VM6365**  
  pdat-1::GFP, pdat-1::ICE  
  - Reported loss of GFP (DA neurons) in late L1 stage  
  - No GFP staining in adults

- **JVR203**  
  pdat-1::GFP, pdat-1::α-synuclein (A53T)  
  - Age dependent loss of dopamine neurons

- **JVR168**  
  pdat-1::GFP, pdat-1::LRRK2 (G2019S)  
  - Age dependent loss of dopamine neurons

- **Dat-1**  
  - loss of activity mutation in dopamine transporter

- **Cat-2**  
  - mutation in biosynthesis of dopamine

- **Dop-3**  
  - mutation in dopamine receptor
Goals

• Correlate loss of dopamine neurons (through loss of GFP signal) to behavioral assays
• Test known LRRK2 inhibitors
• Establish screen for new LRRK2 inhibitors
Autism Spectrum Disorder (ASD), refers to a range of conditions characterized by challenges with social skills, repetitive behaviors, speech and nonverbal communication, as well as by unique strengths and differences.

Neuroligins and neurexins are involved in establishing and maintaining synaptic connections

Mutations in genes for neuroligins and neurexins are associated with ASD
C. elegans Models of Autism Spectrum Disorder

- Disruption of the C. elegans neuroligin-1 gene and the neurexin-1 genes result in sensory deficits.
  - Increased sensitivity to mercury toxicity (Thiomersal)
  - Lack of chemotaxis response to 1-octanol
  - Lack of osmotic avoidance
  - Insensitivity to thermal gradients
  - Behaviors mediated through the ASH neurons

- C. elegans neuroligin deletions can be rescued by microinjection of human wild type neuroligin genes but not by genes carrying mutations associated with ASD.
**Goals of ASD Project**

- Characterize Neuroligin and Neurexin mutants available from C. elegans Genetics Center
- Generate null mutants of NLG-1 and NRX-1 by CRISPR/Cas9 technology
- Confirm/Identify behavioral deficits
- Replace worm NLG-1 and NRX-1 genes with human genes
- Replace worm NLG-1 and NRX-1 genes with human variants associated with ASD
- Develop GRASP (GFP Reconstitution Across Synaptic Partners) assay to screen for restoration of normal function
Goals of ASD Project

- Characterize Neuroligin and Neurexin mutants available from C. elegans Genetics Center
- Generate null mutants of NLG-1 and NRX-1 by CRISPR/Cas9 technology
- Confirm/Identify behavioral deficits
- Replace worm NLG-1 and NRX-1 genes with human genes
- Replace worm NLG-1 and NRX-1 genes with human variants associated with ASD
- Develop GRASP (GFP Reconstitution Across Synaptic Partners) assay to screen for restoration of normal function
Neuroligin and Neurexin Mutants from CGC

• Neuroligin
  – N2 (wt): 16 exons, 845 amino acids
  – VC228: 2341 bp deletion, 334 bp insertion, loss of exons 8-13

• Neurexin
  – N2 (wt): 28 exons, 1716 amino acids
  – VC1416: 861 bp deletion, exon 9 deleted, 54 amino acids
  – SG1: 1498 bp deletion, exons 3-6 deleted, 136 amino acids
VC228 (ok259)

334 bp insertion, 2341 bp deletion

Why isn’t VC228 more defective? Why are only ASH neuron functions affected?

Generate a complete deletion of the NLG-1 gene by CRISPR/Cas9
Neurexin Mutants from CGC

- N2 (wild type): 28 exons, 1716 amino acids
- VC1416: 861 bp deletion
- SG1: ~1500 bp deletion

- Exact location and number of amino acids lost was unknown. Genomic DNA from N2, SG1 and VC1416 was isolated and used as template for PCR to amplify the deleted regions of NRX-1. The PCR products were then sequenced using the Sanger chain termination procedure.
Locate region of deletion by PCR from N2, VC1416 and SG1 genomic DNA
Sequence PCR products showing deletions
Blast sequence of VC1416 and SG1 deletions against N2 genomic DNA
Identify deletion and determine exons and amino acids deleted
1416 Deletion Sequence
Behavioral Assays for Neuroligin and Neurexin Mutants

- Octanol insensitivity
- Increased sensitivity to Thiomersal
- Insensitivity to thermal gradients
## Thermotaxis Assay

<table>
<thead>
<tr>
<th></th>
<th>16°C</th>
<th>20°C</th>
<th>24°C</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>N2</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>X</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IK</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16°C</td>
<td>20°C</td>
<td>24°C</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>N2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>?</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>IK</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Thermotaxis Assay Tc=16**
### Thermotaxis Assay $T_c=24$

<table>
<thead>
<tr>
<th></th>
<th>16°C</th>
<th>20°C</th>
<th>24°C</th>
</tr>
</thead>
<tbody>
<tr>
<td>N2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X</td>
<td></td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>IK</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Behavioral Assays for Neuroligin and Neurexin Mutants

- Octanol insensitivity
- Increased sensitivity to Thiomersal
- Insensitivity to thermal gradients
- Initial experiments failed to replicate literature data
- To better understand the roles of neuroligin and neurexin in synapse creation and function in *C. elegans* we want to completely remove the coding regions of these genes using CRISPR/Cas9.
Goals of ASD Project

• Characterize Neuroligin and Neurexin mutants available from C. elegans Genetics Center

• **Generate null mutants of NLG-1 and NRX-1 by CRISPR/Cas9 technology**

• Confirm/Identify behavioral deficits

• Replace worm NLG-1 and NRX-1 genes with human genes

• Replace worm NLG-1 and NRX-1 genes with human variants associated with ASD

• Develop GRASP (GFP Reconstitution Across Synaptic Partners) assay to screen for restoration of normal function
CRISPR/Cas9 Deletion of *C. elegans NLG-1*

*5’ Flank PCR*  
5’ gRNA

*3’ Flank PCR*  
3’ gRNA

*C. elegans NLG-1 gene*

Null Repair Template

Post selection
Excision of SEC

SEC Self-excising selection cassette  
Roller phenotype  
Hygromycin resistance  
Temperature Induced Cre
Microinjection

• Prepare microinjection plasmid cocktail
  – Repair template (5’and 3’Flanks, SEC and insert)
  – Guide RNA expression plasmids
  – Cas9 expression plasmid
• Inject DNA into the syncytial gonad of young adult hermaphrodites
• After injection, transfer worms to new plate
• After 3 days add hygromycin to plate
• After 6-7 days select viable “rollers” to new plate
• Heat shock L1 larvae at 34C for 4 hours to excise SEC
Goals of ASD Project

• Characterize Neuroligin and Neurexin mutants available from C. elegans Genetics Center
• Generate null mutants of NLG-1 and NRX-1 by CRISPR/Cas9 technology
• **Confirm/Identify behavioral deficits**
• Replace worm NLG-1 and NRX-1 genes with human genes
• Replace worm NLG-1 and NRX-1 genes with human variants associated with ASD
• Develop GRASP (GFP Reconstitution Across Synaptic Partners) assay to screen for restoration of normal function
Goals of ASD Project

• Characterize Neuroligin and Neurexin mutants available from C. elegans Genetics Center
• Generate null mutants of NLG-1 and NRX-1 by CRISPR/Cas9 technology
• Confirm/Identify behavioral deficits
• Replace worm NLG-1 and NRX-1 genes with human genes
• Replace worm NLG-1 and NRX-1 genes with human variants associated with ASD
• Develop GRASP (GFP Reconstitution Across Synaptic Partners) assay to screen for restoration of normal function
**New C. elegans Models of ASD: Humanized Worms**

- We plan to clone the human neuroligin-3 gene, introduce the **R451C** and **G221R** mutations and generate humanized *C. elegans* strains using CRISPR/Cas9; then look for genes or compounds to reverse the effects of the mutations.

- We also plan to clone the human neurexin-2 gene, introduce the **L81Q** mutation and generate humanized *C. elegans* strains using CRISPR/Cas9; then look for genes or compounds to reverse the effects of the mutations.
CRISPR/Cas9 Replacement of C. elegans NLG-1 with Human NLG-3

C. elegans NLG-1 gene

5’ Flank PCR

3’ Flank PCR

5’ gRNA

3’ gRNA

Partial human NLG-3 cDNA

Synthetic DNA Artificial introns

SEC Self-excising selection cassette

Post selection Excision of SEC
Goals of ASD Project

• Characterize Neuroligin and Neurexin mutants available from C. elegans Genetics Center
• Generate null mutants of NLG-1 and NRX-1 by CRISPR/Cas9 technology
• Confirm/Identify behavioral deficits
• Replace worm NLG-1 and NRX-1 genes with human genes
  • Replace worm NLG-1 and NRX-1 genes with human variants associated with ASD
• Develop GRASP (GFP Reconstitution Across Synaptic Partners) assay to screen for restoration of normal function
Site Directed Mutagenesis: R451C

NLG-3

GGT AAG GAC ACC CTG CGA GAG ACC ATC AAG TTC ATG

GGT AAG GAC ACC CTG TGT GAG ACC ATC AAG TTC ATG

PCR with mismatch primer

R451C

GGT AAG GAC ACC CTG TGT GAG ACC ATC AAG TTC ATG
Goals of ASD Project

• Characterize Neuroligin and Neurexin mutants available from C. elegans Genetics Center
• Generate null mutants of NLG-1 and NRX-1 by CRISPR/Cas9 technology
• Confirm/Identify behavioral deficits
• Replace worm NLG-1 and NRX-1 genes with human genes
• Replace worm NLG-1 and NRX-1 genes with human variants associated with ASD
• Develop GRASP (GFP Reconstitution Across Synaptic Partners) assay to screen for restoration of normal function
GRASP: GFP Reconstitution Across Synaptic Partners

NRX-1
GFP11

NLG-1
GFP1-10
GRASP: GFP Reconstitution Across Synaptic Partners

NRX-1
GFP11

NLG-1
GFP1-10
GRASP Screen for Re-Activators of Mutant NLG-3

NRX-1
GFP11

R451C NLG-3
GFP1-10
GRASP Screen for Re-Activators of Mutant NLG-3

Screen for Re-Activators

NRX-1 GFP11 → R451C NLG-3 GFP1-10 → NRX-1 GFP11

Re-Activated NLG-3 GFP1-10
GRASP Screen for Re-Activators of Mutant NLG-3

NRX-1
GFP11

Screen for Re-activators

R451C NLG-3
GFP1-10

NRX-1
GFP11

Re-Activated
NLG-3
GFP1-10
GRASP Screen

- Tag NLG-1 with GFP1-10
- Tag NRX-1 with GFP11
- Generate transgenic worms via CRISPR/Cas9
- Mate to generate hybrids NLG-1 chrX, NRX-1 chrV
  - Alternative: Multiplex CRISPR/Cas9
- Identify synapses
- Tag humanized NLG and NRX genes
- Tag mutant humanized genes
- Screen for compounds to allow formation of GFP with mutant NLG or NRX genes
Acknowledgments

• Students
  – Melissa Medina C’17 Erin Heller C’20
  – Krishnaben Patel C’17 Lexi Holroyd C’20
  – Aidan Antonelli C’18 Leanne Fogarty C’20
  – Erin Connors C’18 Shivani Mody C’21
  – Alina Qasim C’19 Krishna Patel C’21
  – Salma Mahmoud C’19 Stephanie Wang C’22
  – Janaya Reeves C’19 Krishna Patel C’22
  – Stefanie DeFronzo C’20 Mehek Agrawal C’22

• C. elegans Stock Center at University of Minnesota
• Drs. Van Reemdonk, ... for strain donations
• RISE: Research Institute for Scientists Emeriti, Drew University
• Dr. Diane Levitan Merck Research Labs